Oncology & Cancer

Cancer-fighting combination targets glioblastoma

Researchers have paired a specialized diet and a tumor-fighting drug and found the non-toxic combination helps to destroy the two major cells found in an aggressive form of brain cancer, the team reports in the online edition ...

Oncology & Cancer

Researchers test novel gene therapy for glioblastoma

A novel gene therapy clinical trial at University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center is showing promising results, garnering funding with a prestigious U01 Grant from the National Cancer ...

Oncology & Cancer

Novel agent reactivates an immune call by LIF blockade

Results from a study spearhead by researchers at the Vall dĀ“Hebron Institute of Oncology (VHIO), show that the blockade of the multi-functional cytokine LIF induces tumor-infiltrating T cells to target and eliminate cancer. ...

Oncology & Cancer

The evolution of brain tumors

Scientists from the German Cancer Research Center found in a recent study that only three different genetic alterations drive the early development of malignant glioblastomas. At least one of these three cancer drivers was ...

Medications

Bevacizumab may cause cognitive impairment

Glioblastoma is the most common kind of brain tumour in adults. It is a very aggressive form of cancer; patients with this diagnosis have a median post-diagnosis survival of 15 months. Especially in the US, the drug Bevacizumab ...

Oncology & Cancer

At molecular level, cancer mutations echo Darwin's observations

There are more than 100 mutations of the protein behind the deadly brain cancer, glioblastoma, however an international research team has discovered something these mutations have in common. The new understanding could lead ...

Medical research

Novel nanoparticle enhances radiation tumor killing

Radiation kills tumors by creating oxygen free radicals that damage the tumor DNA. However, the lack of oxygen in the center of tumors blocks the production of free radicals, inhibiting radiation killing. NIBIB researchers ...

page 1 from 23

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.

With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.

This text uses material from Wikipedia licensed under CC BY-SA